Dobutamine Hydrochloride Inj · #7 of 35 active shortages by FDA posting duration
Brand: DOBUTAMINE IN DEXTROSE
FDA lists Dobutamine Hydrochloride Inj as Active Shortage (Hospira, Inc., a Pfizer Company).
Availability on file: Unavailable
Dobutamine Hydrochloride Injection: Active Shortage
Unavailable 11 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Dobutamine Hydrochloride Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)
- Package NDC
- 0409-2347-32
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Nov 6, 2017
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Cardiovascular, Pediatric, Renal
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Next Delivery: April 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay
Full Drug Profile
dobutamine
Side effects, interactions, warnings & more
Nearby, Other Dobutamine Shortage Records
Dobutamine Hydrochloride Injection
Hainan Poly Pharm. Co., Ltd.
Injection
Dobutamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dobutamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dobutamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dobutamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
Dobutamine Hydrochloride Injection
Hospira, Inc., a Pfizer Company
Injection
FDA reason on file: Next Delivery: April 2026; Estimated Recovery: June 2026; Shortage per Manufacturer: Manufacturing Delay. General shortage guidance lives on the tracker hub.